- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07504458
Afgørende åben fase 3 klinisk undersøgelse af QTX-2101 hos voksne patienter med akut promyelocytisk leukæmi (QUATRO-APL)
En afgørende åben fase 3-klinisk undersøgelse, der evaluerer effektiviteten og sikkerheden af QTX-2101 i kombination med all-trans-retinsyre hos ny-diagnosticerede patienter med lav-risiko akut promyelocytisk leukæmi
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Rekruttering
- University of Alabama at Birmingham (UAB)
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Kontakt:
- Quetzal Therapeutics Investigator
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Sravanti Rangaraju, MD
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Rekruttering
- City of Hope Comprehensive Cancer Center
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Vinod Pullarkat, MD
-
Irvine, California, Forenede Stater, 92612
- Rekruttering
- University of California, Irvine
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Kiran Naqvi, MD
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- USC Norris Comprehensive Cancer Center
-
Ledende efterforsker:
- Eric Tam, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- UCI Health - UCI Medical Center
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Kiran Naqvi, MD
-
Stanford, California, Forenede Stater, 94305
- Rekruttering
- Stanford University School of Medicine
-
Ledende efterforsker:
- Tian Yi Zhang, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
Ledende efterforsker:
- Marcello Rotta, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory Winship Cancer Institute
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Michael Hochman, MD
-
Augusta, Georgia, Forenede Stater, 30912
- Rekruttering
- Augusta University Medical Center
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Anand Jillella, MD
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Rekruttering
- University of Kentucky Markey Cancer Center
-
Ledende efterforsker:
- Ayman Qasrawi, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Kontakt:
- Quetzal Therapeutics Investigator
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Rekruttering
- University of Maryland Medical Center
-
Ledende efterforsker:
- Maria Baer, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Kontakt:
- Quetzal Therapeutics Investigator
- E-mail: ClinicalTrials@QuetzalTx.com
-
Baltimore, Maryland, Forenede Stater, 21231
- Rekruttering
- Johns Hopkins Kimmel Cancer Center
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Gabriel Ghiaur, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Kontakt:
- Quetzal Therapeutics Investigator
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Dale L Bixby, MD
-
-
New York
-
Buffalo, New York, Forenede Stater, 14203
- Rekruttering
- Roswell Park Comprehensive Cancer Center
-
Ledende efterforsker:
- Eunice Wang, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Aditi Shastri, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina at Chapel Hill
-
Ledende efterforsker:
- Joshua Zeidner, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University Wexner Medical Center
-
Ledende efterforsker:
- Uma Borate, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center
-
Ledende efterforsker:
- Robert Redner, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Sarah Cannon Research Institute at TriStar Centennial Medical Center
-
Ledende efterforsker:
- Steven Strickland, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Ledende efterforsker:
- Farhad Ravandi, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia Health
-
Ledende efterforsker:
- Daniel Reed, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
-
-
-
-
Bordeaux, Frankrig, 33000
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Sud, Centre François Magendie
-
Ledende efterforsker:
- Pierre-Yves Dumas, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
La Tronche, Frankrig, 38700
- Rekruttering
- CHU Grenoble Alpes - Hôpital Michallon
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Martin Carre, MD
-
Nancy, Frankrig, 54500
- Rekruttering
- Centre Hospitalier Régional Universitaire (CHRU) de Nancy - Hôpitaux de Brabois
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Caroline Bonmati, MD
-
Nice, Frankrig, 06202
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Nice - Hôpital de l'Archet 1
-
Ledende efterforsker:
- Thomas Cluzeau, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Paris, Frankrig, 75010
- Rekruttering
- Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis
-
Ledende efterforsker:
- Pierre Fenaux, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Saint-Priest-en-Jarez, Frankrig, 42270
- Rekruttering
- Centre Hospitalier Universitaire (CHU) de Saint-Étienne - Hôpital Nord
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Emmanuelle Tavernier-Tardy, MD
-
Strasbourg, Frankrig, 67000
- Rekruttering
- Hôpitaux Universitaires de Strasbourg
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Marie-Pierre Ledoux, MD
-
-
-
-
-
Roma, Italien, 00133
- Rekruttering
- Hospital Tor Vergata Roma
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Maria Teresa Voso, MD
-
Vicenza, Italien, 36100
- Rekruttering
- Azienda ULSS 8 Berica - Ospedale San Bortolo
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Maria Cristina Miggiano, MD
-
-
-
-
-
Cluj-Napoca, Rumænien, 400015
- Rekruttering
- Institutul Oncologic "Prof. Dr. Ion Chiricuță"
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Minhea Zdrenghea, MD
-
-
-
-
-
Badalona, Spanien, 08916
- Rekruttering
- Institut Català d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol
-
Ledende efterforsker:
- Susana Vives Polo, MD
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Olga Salamero Garcia, MD
-
Barcelona, Spanien, 08041
- Rekruttering
- Hospital de la Santa Creu i Sant Pau
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Ana Garrido Diaz, MD
-
Cáceres, Spanien, 10003
- Rekruttering
- Hospital Universitario San Pedro de Alcántara
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Juan Miguel Bergua Burgúes, MD
-
Málaga, Spanien, 29010
- Rekruttering
- Hospital Regional Universitario de Málaga
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Alejandro Contento Gonzalo, MD
-
Oviedo, Spanien, 33011
- Rekruttering
- Hospital Universitario Central de Asturias
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Maria Teresa Bernal Castillo, MD
-
Valencia, Spanien, 46026
- Rekruttering
- Hospital Universitario y Politécnico La Fe
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Pau Montesinos Fernández, MD
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spanien, 07120
- Rekruttering
- Hospital Universitari Son Espases
-
Kontakt:
- Quetzal Therapeutics Investigator
- Telefonnummer: +13126800501
- E-mail: ClinicalTrials@QuetzalTx.com
-
Ledende efterforsker:
- Andres Novo Garcia, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Informed Consent
- Participants must be between 18 and under 71 years of age
- Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)
- Participants must be classified as low- or intermediate-risk APL
- Participants must be willing and able to comply with the scheduled study visits, treatment plans, laboratory tests, contraception guidance, and other procedures
Exclusion Criteria
- Participants who have significant heart rhythm problems including long QT syndrome, serious arrhythmias, very slow heart rate, or prolonged QTc on ECG
- Participants who have central nervous system leukemia
- Participants having serious ongoing medical conditions or infections including uncontrolled infections, severe organ disease, or conditions that make study participation unsafe
- Participants who are pregnant, breastfeeding, or unwilling to use contraception
- Participants who are unable to safely take study medication, including severe neuropathy, inability to swallow oral medication, malabsorption issues, or known allergy to ATO or ATRA
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: QTX-2101
QTX-2101 (oral arsenic trioxide; ATO) All-trans-retinoic-acid (ATRA; oral) |
The experimental regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, QTX-2101 is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle. |
|
Aktiv komparator: IV ATO
IV Arsenic Trioxide (ATO) All-trans-retinoic-acid (ATRA; oral) |
The comparator regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, IV ATO is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum observed plasma (concentration (Cmax) of QTX-2101 for ASIII
Tidsramme: Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
|
Cmax is defined as the maximum observed plasma concentration following administration of [investigational product], determined from plasma concentration-time data. |
Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
|
|
Molecular complete remission (molecular CR) rate
Tidsramme: Up to 60 days of induction and 3 8-week cycles of consolidation treatment
|
mCR is defined as the absence of detectable PML-RARA fusion transcript in bone marrow assessed by a validated quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay .The mCR rate is defined as the proportion of participants achieving molecular remission at the specified assessment time point following induction and consolidation therapy. |
Up to 60 days of induction and 3 8-week cycles of consolidation treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
At karakterisere hændelsesfri overlevelse (EFS) for QTX-2101/ATRA
Tidsramme: Vurderet i op til 3 år efter den første behandlingsdosis, eller indtil behandlingssvigt (sygdomsprogression), død eller afslutning af studiet, alt efter hvad der indtræffer først
|
Vurderet i op til 3 år efter den første behandlingsdosis, eller indtil behandlingssvigt (sygdomsprogression), død eller afslutning af studiet, alt efter hvad der indtræffer først
|
|
|
To characterize the safety and tolerability of QTX-2101/ATRA and IV ATO/ATRA
Tidsramme: Throughout approximately 10 months of study treatment
|
Treatment emergent adverse events |
Throughout approximately 10 months of study treatment
|
|
Area under the plasma concentration-time curve (AUC) of QTX-2101 for ASIII
Tidsramme: Up to 10 months
|
AUC is defined as the area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC₀-t) and/or extrapolated to infinity (AUC₀-∞), calculated using noncompartmental methods. |
Up to 10 months
|
|
To complete a model-based concentration QT relationship evaluation
Tidsramme: Up to 10 months
|
Time-matched difference in change from baseline in QTcF interval between active treatment and placebo, derived from triplicate 12-lead ECGs at each post-dose time point |
Up to 10 months
|
|
EORTC QLQ-C30 domain unit of measure and measurement tool
Tidsramme: Up to 10 months
|
Change from baseline in EORTC QLQ-C30 global health status (0-100 scale) |
Up to 10 months
|
|
EQ-5D-5L domain unit of measure and measurement tool
Tidsramme: Up to 10 months
|
Change from baseline in EQ-5D-5L index score (0-100) |
Up to 10 months
|
|
Overall Survival
Tidsramme: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
OS is defined as the time from randomization to death from any cause. Participants who are alive at the time of analysis will be censored at the date last known to be alive. |
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
|
Event Free Survival (EFS)
Tidsramme: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
EFS is defined as the time from randomization to the first occurrence of any of the following events: failure to achieve hematologic or molecular remission, relapse (hematologic or molecular), or death from any cause. Participants without an event at the time of analysis will be censored at the date of last adequate disease assessment. |
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer efter histologisk type
- Leukæmi, myeloid
- Leukæmi, Myeloid, Akut
- Hemiske og lymfatiske sygdomme
- Neoplasmer
- Leukæmi
- Hæmatologiske neoplasmer
- Hæmatologiske sygdomme
- Leukæmi, Promyelocytisk, Akut
- Organiske kemikalier
- Retinoider
- Carotenoider
- Polyener
- Alkener
- Kulbrinter, acyklisk
- Kulbrinter
- Cyclohexener
- Cyclohexanes
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Pigmenter, biologisk
- Biologiske faktorer
- Uorganiske kemikalier
- Diterpenes
- Oxider
- Oxygenforbindelser
- A -vitamin
- Arsenicals
- Arsen trioxid
- Tretinoin
Andre undersøgelses-id-numre
- QTX-2101-301
- 2025-524810-28-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .